Our Pricing

Comparing Your NHS vs Private Mounjaro Options

Understanding mounjaro nhs vs private uk options is essential for UK patients seeking tirzepatide treatment for weight management. At Cured Pharmacy, we help thousands of patients navigate the differences between NHS pathways and private prescriptions, offering transparent pricing from £135.00 with same-week access to UK-registered prescribers.

Can You Get Mounjaro on the NHS in the UK?

Mounjaro (tirzepatide) is licensed by the MHRA for weight management in the UK, but NHS availability remains highly restricted [1]. Currently, NHS England has not commissioned widespread access to tirzepatide for obesity treatment, meaning most patients cannot obtain Mounjaro through their GP under standard NHS prescribing.

NICE guidance published in 2023 acknowledged tirzepatide's superior efficacy compared to existing treatments, but funding decisions at Integrated Care Board (ICB) level mean availability varies dramatically across England, Scotland, Wales, and Northern Ireland [2]. Some specialist NHS weight management clinics may prescribe Mounjaro in exceptional circumstances, typically for patients with BMI ≥35 plus significant comorbidities who have failed other interventions.

Waiting lists for NHS specialist weight management services often exceed 12-18 months in many regions, and even after assessment, tirzepatide prescribing remains the exception rather than the rule. For most UK patients seeking Mounjaro, private prescription represents the only practical access route.

NHS Mounjaro Eligibility Criteria vs Private Requirements

Where NHS prescribing does occur, eligibility criteria are stringent. Patients typically need BMI ≥35 with at least one weight-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea), documented evidence of structured weight management attempts including dietary modification and increased physical activity, and willingness to participate in ongoing specialist monitoring [3].

Private prescription services like Cured Pharmacy follow MHRA-licensed prescribing guidelines but offer broader access. Our UK-registered prescribers assess patients with BMI ≥30 (or ≥27 with weight-related health conditions) through a comprehensive online consultation, typically completed in under three minutes. Clinical assessment considers your medical history, current medications, contraindications, and weight management goals.

All prescription treatments require approval by a UK prescriber, whether NHS or private. The key difference lies in waiting times, specialist referral requirements, and funding availability rather than clinical safety standards.

What the Assessment Covers

Your UK prescriber will review cardiovascular history, thyroid function, history of pancreatitis, diabetic retinopathy status, and current medications that may interact with GLP-1 receptor agonists. This ensures tirzepatide is clinically appropriate and safe for your individual circumstances, regardless of whether you access treatment via NHS or private routes.

Private Mounjaro Costs: What to Expect in the UK

Private Mounjaro prescriptions in the UK start from £135.00 at Cured Pharmacy, representing competitive pricing compared to typical market rates. Your final cost depends on the prescribed dose, which your UK prescriber determines based on your response and tolerability during dose escalation.

Mounjaro follows a structured dose escalation schedule starting at 2.5mg weekly, increasing every four weeks to 5mg, 7.5mg, 10mg, 12.5mg, and potentially 15mg as the maintenance dose [1]. Each dose strength is priced transparently before you complete your consultation, with no hidden fees or subscription lock-ins.

Unlike NHS pathways where medication costs are covered (subject to standard prescription charges in England), private prescriptions require you to pay the full medication cost. However, private access eliminates 12-18 month waiting lists, specialist referral requirements, and geographical postcode lottery issues that affect NHS availability.

What's Included in the Price

Your Mounjaro prescription from Cured Pharmacy includes free UK prescriber consultation, genuine UK-licensed medication dispensed by our GPhC-registered pharmacy (9012511), discreet packaging, and delivery to your UK address. Ongoing prescriptions require follow-up consultations to monitor progress and adjust dosing as clinically appropriate.

How Mounjaro Works: The Science Behind Tirzepatide

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, gastric emptying, and insulin secretion.

In the SURMOUNT-1 trial, participants receiving tirzepatide 15mg achieved an average 22.5% body weight reduction over 72 weeks, significantly outperforming placebo and exceeding results seen with semaglutide-based treatments in head-to-head comparisons [1][4]. Approximately 63% of participants on the highest dose achieved at least 20% weight loss, a threshold rarely reached with lifestyle interventions alone.

Clinical trials demonstrated that tirzepatide's dual mechanism produces superior glycaemic control and weight reduction compared to single GLP-1 agonists, though individual responses vary [1]. All participants in registration trials followed structured diet and exercise programmes alongside medication, reflecting real-world prescribing expectations.

NHS Waiting Times vs Private Access Speed

NHS specialist weight management referrals typically involve 12-18 month waiting lists in most UK regions, with some areas reporting delays exceeding two years. Even after initial assessment, patients may undergo further dietary and behavioural interventions before medication is considered, adding 6-12 months to the timeline [3].

Private prescription services offer same-week access in most cases. At Cured Pharmacy, patients complete an online consultation reviewed by UK prescribers typically within 24-48 hours on weekdays. Once approved, medication is dispensed from our GPhC-registered pharmacy and dispatched for next-day delivery across the UK.

This time difference can be clinically significant. Earlier intervention in weight management may reduce progression of obesity-related complications including type 2 diabetes, cardiovascular disease, and osteoarthritis. However, medication alone is not sufficient—both NHS and private pathways emphasise the importance of sustained lifestyle modification for long-term success.

Ongoing Monitoring Requirements

Whether prescribed via NHS or private routes, Mounjaro requires ongoing clinical monitoring. Private patients should maintain regular contact with their GP for blood pressure checks, HbA1c monitoring if diabetic, and assessment of weight-related comorbidities. Cured Pharmacy prescribers review progress at each prescription renewal, but your NHS GP remains responsible for overall health management and should be informed of any private prescriptions.

Alternative Weight Loss Treatments Available Privately

If Mounjaro is not clinically suitable or you prefer alternative options, several other prescription weight loss treatments are available through private UK pharmacies. Wegovy contains semaglutide, a single GLP-1 receptor agonist that demonstrated 14.9% average weight loss over 68 weeks in the STEP-1 trial [5]. Saxenda uses daily liraglutide injections, offering a shorter-acting GLP-1 option for patients who prefer daily dosing control.

Oral medications including orlistat (available as prescription-strength Xenical or lower-dose Alli and Orlos) work through a different mechanism, blocking approximately 30% of dietary fat absorption. These treatments suit patients who prefer tablets over injections or have contraindications to GLP-1 therapies [6].

Your UK prescriber will discuss which treatment aligns best with your medical history, lifestyle preferences, and weight management goals. Some patients transition between treatments based on response, tolerability, and changing clinical circumstances. All prescription options require ongoing lifestyle modification including reduced calorie intake and increased physical activity for optimal results.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating type 2 diabetes [TA924]. NICE. https://www.nice.org.uk/guidance/ta924
3. Astbury, N. M., Aveyard, P., Nickless, A., et al. (2018). Doctor Referral of Overweight People to Low Energy total diet replacement Treatment (DROPLET): pragmatic randomised controlled trial. BMJ, 362, k3760. https://doi.org/10.1136/bmj.k3760
4. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
5. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
6. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to prescribed treatment alongside sustained lifestyle modification including reduced calorie intake and increased physical activity.